Concepts (95)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Education, Pharmacy | 5 | 2020 | 57 | 1.510 |
Why?
|
| Problem-Based Learning | 3 | 2017 | 42 | 1.060 |
Why?
|
| Teaching | 2 | 2017 | 59 | 0.940 |
Why?
|
| Students, Pharmacy | 4 | 2020 | 58 | 0.770 |
Why?
|
| Vaccination | 5 | 2025 | 355 | 0.760 |
Why?
|
| Louisiana | 8 | 2025 | 50 | 0.600 |
Why?
|
| Schools, Pharmacy | 2 | 2017 | 19 | 0.570 |
Why?
|
| Respiratory Tract Infections | 2 | 2016 | 36 | 0.560 |
Why?
|
| International Educational Exchange | 1 | 2017 | 2 | 0.550 |
Why?
|
| Vaccines | 3 | 2023 | 65 | 0.540 |
Why?
|
| Clinical Clerkship | 1 | 2017 | 27 | 0.540 |
Why?
|
| Travel | 2 | 2016 | 36 | 0.480 |
Why?
|
| Microbial Sensitivity Tests | 3 | 2016 | 245 | 0.470 |
Why?
|
| Intensive Care Units | 2 | 2016 | 72 | 0.460 |
Why?
|
| Bacterial Infections | 1 | 2015 | 45 | 0.440 |
Why?
|
| Trauma Centers | 1 | 2015 | 92 | 0.430 |
Why?
|
| Patient Simulation | 1 | 2014 | 14 | 0.430 |
Why?
|
| Computer-Assisted Instruction | 1 | 2014 | 26 | 0.420 |
Why?
|
| Immunization Programs | 2 | 2024 | 25 | 0.410 |
Why?
|
| Arabs | 1 | 2013 | 19 | 0.390 |
Why?
|
| Fellowships and Scholarships | 1 | 2012 | 32 | 0.360 |
Why?
|
| Computer Simulation | 1 | 2014 | 408 | 0.360 |
Why?
|
| Bacteria | 1 | 2015 | 293 | 0.360 |
Why?
|
| Decision Making | 2 | 2024 | 249 | 0.350 |
Why?
|
| Faculty | 1 | 2012 | 105 | 0.340 |
Why?
|
| Acculturation | 1 | 2013 | 205 | 0.340 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2022 | 760 | 0.320 |
Why?
|
| Iraq | 3 | 2024 | 8 | 0.320 |
Why?
|
| Humans | 23 | 2025 | 43102 | 0.300 |
Why?
|
| Cross-Sectional Studies | 6 | 2024 | 3156 | 0.270 |
Why?
|
| Anti-Infective Agents | 2 | 2017 | 75 | 0.240 |
Why?
|
| Curriculum | 3 | 2020 | 318 | 0.230 |
Why?
|
| Respiratory Tract Diseases | 1 | 2025 | 31 | 0.230 |
Why?
|
| Immunization Schedule | 1 | 2024 | 9 | 0.220 |
Why?
|
| Delivery of Health Care | 2 | 2024 | 310 | 0.210 |
Why?
|
| Community Pharmacy Services | 1 | 2023 | 25 | 0.200 |
Why?
|
| Burnout, Professional | 1 | 2023 | 31 | 0.200 |
Why?
|
| Trust | 1 | 2024 | 167 | 0.190 |
Why?
|
| Infant | 1 | 2024 | 1175 | 0.170 |
Why?
|
| Motivation | 1 | 2024 | 513 | 0.160 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2025 | 497 | 0.160 |
Why?
|
| Pharmacy | 1 | 2020 | 34 | 0.160 |
Why?
|
| Child, Preschool | 1 | 2024 | 1546 | 0.160 |
Why?
|
| Infant, Newborn | 1 | 2022 | 972 | 0.150 |
Why?
|
| Female | 5 | 2025 | 24698 | 0.150 |
Why?
|
| Cohort Studies | 1 | 2022 | 1759 | 0.140 |
Why?
|
| Male | 5 | 2025 | 23409 | 0.130 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2024 | 989 | 0.130 |
Why?
|
| Adolescent | 2 | 2022 | 6081 | 0.130 |
Why?
|
| International Cooperation | 1 | 2016 | 52 | 0.120 |
Why?
|
| Acinetobacter | 1 | 2016 | 9 | 0.120 |
Why?
|
| Internationality | 1 | 2016 | 37 | 0.120 |
Why?
|
| Congresses as Topic | 1 | 2016 | 50 | 0.120 |
Why?
|
| Cooperative Behavior | 1 | 2017 | 269 | 0.120 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2016 | 63 | 0.120 |
Why?
|
| Adult | 5 | 2025 | 13872 | 0.120 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2016 | 90 | 0.110 |
Why?
|
| Postoperative Complications | 1 | 2017 | 263 | 0.110 |
Why?
|
| Staphylococcus aureus | 1 | 2016 | 94 | 0.110 |
Why?
|
| Educational Measurement | 1 | 2014 | 102 | 0.100 |
Why?
|
| Young Adult | 2 | 2014 | 5080 | 0.090 |
Why?
|
| Pharmacists | 2 | 2023 | 61 | 0.090 |
Why?
|
| Internet | 1 | 2014 | 236 | 0.090 |
Why?
|
| Qatar | 1 | 2012 | 1 | 0.090 |
Why?
|
| Anti-Bacterial Agents | 1 | 2016 | 432 | 0.090 |
Why?
|
| Middle Aged | 4 | 2025 | 12222 | 0.090 |
Why?
|
| Retrospective Studies | 2 | 2016 | 2544 | 0.090 |
Why?
|
| United States | 2 | 2022 | 5205 | 0.080 |
Why?
|
| Time Factors | 1 | 2013 | 1857 | 0.070 |
Why?
|
| Prevalence | 1 | 2013 | 1612 | 0.070 |
Why?
|
| Risk Factors | 1 | 2013 | 3994 | 0.050 |
Why?
|
| Feedback | 1 | 2023 | 56 | 0.050 |
Why?
|
| Professional Role | 1 | 2023 | 40 | 0.050 |
Why?
|
| Models, Educational | 1 | 2022 | 46 | 0.050 |
Why?
|
| Health Facilities | 1 | 2022 | 32 | 0.050 |
Why?
|
| Follow-Up Studies | 1 | 2025 | 1067 | 0.050 |
Why?
|
| New Orleans | 1 | 2022 | 17 | 0.050 |
Why?
|
| Aged | 2 | 2025 | 8214 | 0.050 |
Why?
|
| Cultural Competency | 1 | 2022 | 138 | 0.040 |
Why?
|
| Hospitals | 1 | 2022 | 117 | 0.040 |
Why?
|
| Focus Groups | 1 | 2023 | 423 | 0.040 |
Why?
|
| Public Health | 1 | 2024 | 424 | 0.040 |
Why?
|
| Drug Compounding | 1 | 2020 | 93 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2023 | 574 | 0.040 |
Why?
|
| Blood Glucose | 1 | 2022 | 389 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2023 | 1600 | 0.040 |
Why?
|
| Residence Characteristics | 1 | 2022 | 363 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2023 | 706 | 0.030 |
Why?
|
| Drug Resistance, Microbial | 1 | 2016 | 27 | 0.030 |
Why?
|
| Preceptorship | 1 | 2016 | 10 | 0.030 |
Why?
|
| Imipenem | 1 | 2016 | 3 | 0.030 |
Why?
|
| Vancomycin | 1 | 2016 | 7 | 0.030 |
Why?
|
| Ciprofloxacin | 1 | 2016 | 16 | 0.030 |
Why?
|
| Child | 1 | 2022 | 3443 | 0.030 |
Why?
|
| Prognosis | 1 | 2016 | 861 | 0.030 |
Why?
|